Cemiplimab is a monoclonal antibody that attaches to the PD-1 protein on the body's immune cells. Cemiplimab may work by stopping cancer cells from being able to inhibit the body's immune system.
| SparkCures ID | 322 |
|---|---|
| Generic Name | Cemiplimab (REGN2810) |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
There are no resources, links or videos to display for this treatment.